Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (NASDAQ: ACOG) 2Q26

Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. (NASDAQ: ACOG), highlighting the company's second-quarter 2026 results, which show accelerating demand for its Alzheimer's treatment ZUNVEYL. The company reported net product revenue of $6.0 million, a 71% increase quarter-over-quarter, with bottles dispensed rising 37% to 8,294. June was the strongest month since launch, with 2,997 bottles dispensed, and management indicated that growth continued into the third quarter.

The results are particularly notable given that they were achieved without significant stocking benefits or broader formulary wins. Downstream pharmacy benefit manager (PBM) implementation remained at approximately 16%, suggesting that the growth was driven primarily by underlying demand and improved commercial execution. This indicates a higher quality of earnings, as prescriptions, repeat use, and facility adoption all advanced despite the limited payer access.

Adoption is broadening across the healthcare spectrum. In the second quarter, Alpha Cognition saw 1,347 quarterly prescribers, 1,024 repeat prescribers, and 1,908 cumulative writers. Additionally, 1,095 long-term care (LTC) facilities generated prescriptions during the quarter. This expanding prescriber and facility base, combined with deepening repeat utilization, provides a meaningful growth path. As PBM implementation progresses, it could serve as an additional catalyst for revenue growth.

The company is also balancing commercial investment with a growing evidence base. Alpha Cognition lowered its full-year 2026 research and development (R&D) and selling, general, and administrative (SG&A) guidance to $50 million-$54 million, while maintaining its 2027 operating profitability target. Several key milestones are expected in the near term: the CONVERGE data are anticipated in the third quarter of 2026, the RESOLVE study is underway, and the sublingual program is gated by comparative pharmacokinetic (PK) results. These developments could provide additional upside as the company moves toward greater operating leverage.

Stonegate Capital Partners' update underscores the company's progress in establishing ZUNVEYL in the market. The robust demand in the absence of broad payer coverage suggests that the product is gaining traction among prescribers and facilities. With white space remaining across homes and physicians, and with utilization deepening, the core setup appears strong. The potential for broader PBM implementation adds an incremental growth driver that could further accelerate revenue.

The company's financial discipline, reflected in the lowered guidance, indicates a focus on achieving profitability. The upcoming data readouts and clinical milestones will be critical in validating the product's efficacy and safety profile, potentially influencing future adoption and reimbursement decisions.

Overall, Alpha Cognition's second-quarter performance demonstrates that ZUNVEYL is gaining momentum in the market. The combination of increasing demand, expanding prescriber base, and a clear path to additional growth catalysts positions the company favorably as it continues to execute on its commercial strategy. Investors and stakeholders will be watching closely for the upcoming clinical data and any developments in payer coverage that could further impact the company's trajectory.